Perrier ordered to remove water filters
Regional French authorities ordered Nestle on Wednesday to remove a system that filters Perrier and to renew its authorisation to call it natural mineral water, marking the latest turn in a saga that has ensnared the government.
The senior public official in France's southern Gard region, where the source for Perrier is located and where the water is bottled, said the order does not imply any risk for consumers.
But having to remove the filtering system within two months and obtain reauthorisation to call Perrier natural mineral water was another blow for its owner Nestle Waters.
The unit of the Swiss food and drinks conglomerate has been under pressure for some time over Perrier and other brands as EU regulations strictly limit what treatments are allowed for what is marketed as natural mineral water.
A French magistrate opened earlier this year a fraud inquiry into Nestle and rival bottler Sources Alma over suspicions of illegal processing of mineral waters that command a premium price following complaints by consumer groups.
In 2024, Nestle Waters admitted using banned filters and ultra-violet treatment on mineral waters, which must be processed naturally by law.
It paid a two-million-euro ($2.2-million) fine to avoid legal action over the use of illegal water sources and filtering, and said at the time the replacement filters were approved by the government and that its water is "pure".
However, experts at the regional health authority judged the microfiltering system in place wasn't compliant with regulations, prompting Wednesday's order.
The possibility that the government may have turned a blind eye to illegal filtering practices has been under investigation by a French senate committee following media reports that the prime minister's office and president's office had in 2023 recommended letting Nestle carry on with the microfiltering of water despite warnings from the government health service.
France's former director general of health, Jerome Salomon, had called for the suspension of Nestle's operations permit at its sites that produce Vittel and other brands in the Vosges region of eastern France and Perrier at Vergeze in the southern Gard region.
President Emmanuel Macron has denied giving in to lobbying by the Swiss food giant.
"One illegal treatment has been replaced by another. The government, which had approved Nestle Waters's transformation plan, is heavily at fault," said socialist Senator Alexandre Ouizille, who is leading the Senate investigation which is due to be published on May 19.
Foodwatch, one of the consumer groups that had spoken out publicly about the practices of bottlers, said Wednesday "this decision goes in the right direction" and expressed hope that the investigation underway will "shed complete light on the actions committed by the multinational and its executives".
ysp-siu-cho/rl/djt
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
UBS Capital Requirements Rise Following Switzerland's Proposal
Switzerland's Federal Department of Finance ('FDF') has proposed stricter rules for UBS Group AG UBS following its takeover of Credit Suisse. The move has been attempted to reduce the risks of another Credit Suisse-style Swiss government has proposed that UBS should fully capitalize its foreign subsidiaries, up from the current 60% threshold. This will require UBS to increase its common equity tier-one capital by up to $26 bank will be allowed to reduce its Additional Tier 1 (AT1) bond holdings by $8 billion. Still, this will result in a net increase of $18 billion in FDF stated, 'The Credit Suisse crisis made it clear that the Swiss parent bank's capital base was insufficient. The implementation of the package of measures is intended to substantially reduce the likelihood that another systemically important bank in Switzerland will get into a severe crisis, and that emergency measures by the state will be required.'Per the FDF, this estimate assumed no change in UBS's balance sheet size, risk-weighted assets or its potential use of mitigation said it 'strongly disagrees with the extreme increase in capital requirements that has been proposed. These changes would result in capital requirements that are neither proportionate nor internationally aligned.'Notably, the 'too big to fail' proposals (still subject to parliamentary approval) have come after the Swiss financial regulator granted capital relief to Credit Suisse in 2017, allowing the bank to inflate the value of its foreign the new capital proposals will be put out for consultation before being submitted to the the FDF, the proposed reforms will not become law before 2028, and UBS will be given a six to eight-year transition period to implement the changes once the legislation comes into force. UBS took over its rival Credit Suisse in a state-sponsored rescue in then, UBS has been facing challenges and legal claims, which is increasing costs. Last month, UBS agreed to pay $511 million to resolve a tax probe by the U.S. Department of Justice against Credit Suisse for preparing false income tax returns and tax UBS is on track to substantially complete the integration of Credit Suisse by the end of 2026 and, hence, achieve the targeted cost the first quarter of 2025, UBS completed consolidating its branch network in Switzerland, merging 95 branches since the July 2024 merger with Credit Suisse. The company is initiating its Swiss business migrations and aims to complete the migrations by the first quarter of the first quarter of 2025, UBS realized an additional $0.9 billion in gross cost savings. Cumulative gross cost savings at the end of the first quarter of 2025 amounted to $8.4 billion compared with the 2022 combined cost base of UBS and Credit Suisse. This represents around 65% of its ambition to deliver $13 billion in annualized exit rate gross cost savings by the end of 2026. Over the past six months, UBS shares have gained 6.1% compared with the industry's growth of 23.1%. Image Source: Zacks Investment Research Currently, UBS carries a Zacks Rank #3 (Hold). A couple of better-ranked peer stocks are Deutsche Bank Aktiengesellschaft DB and Mitsubishi UFJ Financial Group, Inc. MUFG, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks estimates for DB for the current year have been revised 4.2% upward over the past 60 days. Over the past six months, DB shares have soared 57.7%.MUFG's current fiscal-year earnings estimates have been revised 4.6% higher over the past 60 days. MUFG shares have gained 16.5% over the past six months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report UBS Group AG (UBS) : Free Stock Analysis Report Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Canada plans to hit NATO spending target early and reduce reliance on US defense, Carney says
Canada will meet NATO's military spending guideline by early next year and diversify defense spending away from the United States, Prime Minister Mark Carney said Monday, asserting that Washington no longer plays a predominant role on the world stage. The announcement means Canada will achieve NATO's spending target of 2% of gross domestic product five years earlier than previously planned. 'Our military infrastructure and equipment have aged, hindering our military preparedness,' Carney said. 'Only one of our four submarines is seaworthy. Less than half of our maritime fleet and land vehicles are operational. More broadly, we are too reliant on the United States.' According to NATO figures, Canada was estimated to be spending 1.45% of GDP on its military budget, below the 2% target that NATO countries have set for themselves. Canada previously said it was on track to meet NATO's target by the end of the decade. 'Our goal is to protect Canadians, not to satisfy NATO accountants,' Carney said in a speech at the University of Toronto. Canada is about to host US President Donald Trump and other leaders at a summit of the Group of Seven leading industrialized nations in Alberta on June 15-17, and before the NATO summit in Europe. NATO allies are poised to increase the commitment well beyond the 2% target. NATO Secretary-General Mark Rutte said last week that most US allies at NATO endorse Trump's demand that they invest 5% of gross domestic product on their defense needs and are ready to ramp up security spending even more. 'We are meeting 2%. And that is the NATO target as it is today,' Carney said at a later news conference. 'We will need to spend more.' He said there will be discussions on the increased spending amount and its timeline at the NATO summit. Carney has said he intends to diversify Canada's procurement and enhance the country's relationship with the EU. 'We should no longer send three-quarters of our defense capital spending to America,' Carney said in a speech at the University of Toronto. 'We will invest in new submarines, aircraft, ships, armed vehicles and artillery, as well as new radar, drones and sensors to monitor the seafloor and the Arctic.' Canada has been in discussions with the European Union to join an EU drive to break its security dependency on the United States, with a focus on buying more defense equipment, including fighter jets, in Europe. Carney's government is reviewing the purchase of U.S. F-35 fighter jets to see if there are other options. 'We stood shoulder to shoulder with the Americans throughout the Cold War and in the decades that followed, as the United States played a predominant role on the world stage. Today, that predominance is a thing of the past,' Carney said in French, one of Canada's official languages. He added that with the fall of the Berlin Wall in 1989, the United States became the global hegemon, noting that its strong gravitational pull became virtually irresistible and made the US 'our closest ally and dominant trading partner.' 'Now the United States is beginning to monetize its hegemony: charging for access to its markets and reducing its relative contributions to our collective security,' Carney said. Trump's calls to make Canada the 51st US state have infuriated Canadians, and Carney won the job of prime minister after promising to confront the increased aggression shown by Trump. The prime minister said 'a new imperialism threatens.' Carney said the long-held view that Canada's geographic location will protect Canadians is increasingly archaic. The government is adding $9 billion Canadian (US$6.6 billion) in spending this year and Carney said the Canadian Coast Guard will be now be a part of the military. European allies and Canada have already been investing heavily in their armed forces, as well as on weapons and ammunition, since Russia launched a full-scale invasion of Ukraine on Feb. 24, 2022.
